Iruplinalkib for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This real-world study looks at how effective Iruplinalkib is for people with ALK-positive non-small cell lung cancer. It is open to patients who have already taken this drug, and will simply collect data from your regular medical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with ALK-positive non-small cell lung cancer.
- You must have already taken Iruplinalkib (WX-0593) as part of your treatment.
- You must be at least 18 years old.
- You cannot be pregnant or breastfeeding.
- You must not have ongoing lung conditions like interstitial lung disease or drug-related pneumonitis that require medical care.
- You must agree to let the researchers use your medical data for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks people with advanced ALK-positive lung cancer who are taking or will start Iruplinalkib. It checks how well Iruplinalkib works in the real world and monitors safety.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
This trial tests whether taking Iruplinalkib pills after lung cancer surgery can lower the risk of cancer returning in people with stage IA ALK-positive non-small cell lung cancer that has high-risk features.
This trial tests whether taking Iruplinalkib before surgery can help people with ALK-positive non-small cell lung cancer (NSCLC) that has not spread too far. The goal is to see if the drug shrinks the tumor enough for successful removal.
This trial is studying why lung cancer that has spread to the brain responds to treatment by looking at the fluid around the brain and spine. It may help doctors understand how to better treat people with ALK-positive lung cancer who have brain metastases.
This trial tests a new targeted pill (Iruplaltinib) combined with chemotherapy before surgery for patients with a specific type of lung cancer (ALK-positive non-squamous NSCLC). The goal is to shrink the tumor to make surgery more successful and potentially improve outcomes. This approach is called neoadjuvant therapy, meaning it's given before the main treatment (surgery).
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.